VYVGART HYTRULO: payments to doctors
Payments that named VYVGART HYTRULO as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $3.1M
- Providers
- 7,224
- Transactions
- 34,285
- Average per transaction
- $91
The per-transaction average — $91 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 7,224 providers the average total is $430, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Argenx US, Inc. | $3,106,935 | 100.0% |